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Rheumatoid arthritis (RA) is a chronic autoimmune disease and one of the leading causes of disability in the USA. Although
certain biological therapies, including protein and antibodies targeting inﬂammatory factors such as the tumor necrosis factor,
are eﬀective in reducing symptoms of RA, these treatments do not reverse disease. Also, although novel gene therapy approaches
have shown promise in preclinical and clinical studies to treat RA, it is still unclear whether gene therapy can be readily and
safely applied to treat the large number of RA patients. Recently, nanosized, endocytic-derived membrane vesicles “exosomes”
were demonstrated to function in cell-to-cell communication and to possess potent immunoregulatory properties. In particular,
immunosuppressive DC-derived exosomes and blood plasma- or serum-derived exosomes have shown potent therapeutic eﬀects
in animal models of inﬂammatory and autoimmune disease including RA. This paper discusses the current knowledge on the
production, eﬃcacy, mechanism of action, and potential therapeutic use of immunosuppressive exosomes for arthritis therapy.
1.Introduction
Arthritis refers to joint inﬂammation resulting from an
autoimmune disease, joint wear and tear, or bacterial/viral
infection. Rheumatoid arthritis (RA) is a chronic, systemic
autoimmune disorder in which endogenous synovial joints
and other connective tissues are attacked by the immune
cells. The pathological inﬁltration of inﬂammatory cells
and synovial hyperplasia usually leads to the progressive
destruction of articular cartilage and ankylosis of the joints.
Although diﬀerent types of treatment are available to allevi-
atesymptomsand/orimprovediseasepathologies,noknown
therapy has been eﬀective in reversing disease progression.
Conventional therapies for RA include nonsteroidal anti-
inﬂammatory drugs, steroids, so-called “disease-modifying
medications” (DMARDs), and surgery. These therapies are
mostly palliative, can cause signiﬁcant side eﬀects, and oﬀer
no cure for the disease. In the early 1990s, biological ther-
apies were demonstrated to alleviate symptoms of disease,
butnottonecessarilycuredisease.Currentlyseveraldiﬀerent
biologics, in particular inhibitors of tumor necrosis factor-
α (TNF-α), are the leading drugs for treating RA. However,
the need for constant infusion of drugs, either intravenously
or subcutaneously, as well as the fact that not all patients
response to anti-TNF therapy, necessitates the development
of new RA therapies.
Gene therapy approaches also have been developed to
treat arthritis and related joint disorders, demonstrated to
be highly therapeutic in many animal models and safe in
several clinical trials [1–3]. Gene transfer can be used to
deliver genes encoding factors that inhibit proinﬂammatory
cytokines (e.g., IL-1 receptor antagonist (IL-1Ra) for IL-
1β inhibition, TNF receptor for TNF-α inhibition, and
IL-18 neutralizer), Th2-polarizing and anti-inﬂammatory
cytokines (e.g., IL-4, IL-10 and TGF-β), apoptosis-inducing
factor (e.g., FasL), NF-κB inhibitors or decoy oligodeoxynu-
cleotides, or cartilage destruction inhibitor (e.g., Ribozymes
and MMP-1 antisense construct), either locally to the
inﬂamed joints or systemically [4–7]. The types of vectors
for gene delivery include nonviral (e.g., plasmid DNA) and
viral (e.g., retrovirus, adenovirus, adenoassociated virus,
lentivirus and herpes simplex virus) vectors. The potential
problems with in vivo gene transfer using viral vectors
include possible toxicity and immunogenicity [8, 9]. Among2 International Journal of Rheumatology
thesevectors,adenoassociatedvirusvector,whichhaslimited
immunogenicity and toxicity, has been used safely in several
PhaseIandIIgenetherapytrialsforgenetransferoftheTNF
soluble receptor locally to joints.
Ex vivo gene transfer is an alternative gene delivery
strategy where cells are genetically modiﬁed in vitro fol-
lowed by local or systemic injection. The advantages of
ex vivo gene transfer include better safety by controlling
the type of cells transduced and reduced immunogenicity
following injection. Synovial ﬁbroblasts (SFs) or ﬁbroblast-
like synoviocytes (FLS) have been a major target for ex
vivo gene transfer in RA therapy. Intra-articular injection
of virally transduced SFs expressing IL-1Ra was therapeutic
in animal models of arthritis [10–12] and a clinical study
using IL-1Ra-transduced autologous RASFs for injection
into knuckle joints of RA patients showed evidence of
therapeutic eﬀects without any adverse events [13]. Still,
RASFs have the problems of low transduction eﬃciency and
low proliferation rate which hamper their application on a
large scale [14]. In addition to RASFs, dendritic cells (DCs,
discussed below) as well as antigen-speciﬁc T cells [15]h a v e
also been used as vehicles to deliver immunosuppressive
cytokines for the treatment of collagen-induced arthritis
(CIA) in mouse models.
DCs are antigen-presenting cells (APCs) derived from
CD34+ stem cells that can regulate immune reactivity.
Although DC were initially considered as instigators of
immune responses, including organ graft rejection and
autoimmunedisorders,morerecentdatahaveimplicatedDC
in the induction and even maintenance of tolerance to allo-
or autoantigens in experimental models. The ability of DC to
either stimulate or suppress immune responses is mediated
by various factors; the most important being their stage of
diﬀerentiation/maturation/activation and their hematopoi-
etic lineage aﬃliation. Immature DCs, characterized by low
levels of MHC and costimulatory molecules (e.g., CD80,
CD86, CD40, ICAM-1, and ICOSL), are able to suppress
antigen-speciﬁc T-cell responses. These “tolerogenic” DCs
produce reduced levels of type 1 cytokines (e.g., IL-12
family members) and increased level of immunosuppressive
cytokines (e.g., IL-10, TGF-β, and VEGF). They can also
express high levels of the tryptophan catabolizing enzyme
indoleamine 2,3-dioxygenase (IDO), which degrades free
tryptophan and “starves” responder T cells of the essential
amino acid, resulting in increased T-cell apoptosis [16]. The
mechanismsthroughwhichtolerogenicDCsexertregulatory
functions can include the induction of antigen-speciﬁc T-
cell anergy or deletion [17]; induction of regulatory T
cells [18–20]; polarization of T cells away from a Th1
or Th17-type response and toward a Th2-type response
[21]. The immunosuppressive/tolerogenic properties of DCs
can be enhanced and stabilized by genetic modiﬁcation.
Genetically modiﬁed DCs have been shown to successfully
ameliorate symptoms and control disease progression in
animal autoimmune disease models including RA and type 1
diabetes [22–26]. In fact, DCs transduced with viral vectors
expressingimmunosuppressiveagentswerefoundtobemore
eﬀective in treating murine CIA than similarly modiﬁed
ﬁbroblasts or T cells [22, 27].
More recently, exosomes derived from immunosup-
pressive DCs have been found to confer potent and last-
ing immunosuppressive eﬀects, similar to their parental
DC. Exosomes are a type of secreted membrane vesicles
produced by most cell types. They are characterized by
a size of 30–100nm in diameter and an endocytic ori-
gin, formed by the reverse budding of the multivesicular
bodies and released upon their fusion with the plasma
membrane [28–30]( Figure 1(a)). Their protein content
largely reﬂects that of the parental cells and is enriched in
certain molecules including adhesion molecules, membrane
traﬃcking molecules, cytoskeleton molecules, heat-shock
proteins, cytoplasmic enzymes, signal transduction proteins,
andcell-speciﬁcantigens[28,31,32].APC-derivedexosomes
are enriched in MHC classes I and II as well as co-
stimulatory molecules. Exosomes also contain functional
mRNA and microRNAs molecules [33–35]( Figure 1(b)).
Most hematopoietic cells, including DCs, produce copious
amount of exosomes. Certain types of exosomes have been
shown to confer immunosuppressive eﬀects in diﬀerent
disease models including RA. Thus it is likely that exosomes
represent a novel eﬀective and safe therapeutic approach for
treating arthritis. Indeed, exosomes derived from immuno-
suppressive DCs and from peripheral blood (Figure 2)h a v e
shown the ability to suppress inﬂammation.
2. ImmunosuppressiveDC-DerivedExosomes
for Arthritis Treatment
2.1. DC/IL-10 Exosomes. DCs transduced with adenovirus
expressing the IL-10 gene (Ad.IL-10) or treated with
recombinant murine IL-10 (rmIL-10) were demonstrated
to be anti-inﬂammatory and suppress mouse CIA [36, 38].
Interestingly, exosomes secreted by those DCs were also
found immunosuppressive. Exosomes derived from Ad.IL-
10 DCs were capable of decreasing T-cell proliferation in
a mixed lymphocytes reaction. In mice immunized with
keyhole limpet hemocyanin (KLH) antigen, local injection
of DCs (ad.vIL-10 or rmIL-10 treated) or their exosomes
both resulted in signiﬁcant suppression of KLH-induced
delayed-type hypersensitivity (DTH) response. Moreover, a
single dose of these exosomes systemically delivered after the
onset of CIA eﬀectively ameliorated disease progression, in
contrast to the ineﬀectiveness of direct injection of rmIL-10
[36].SimilareﬃcacywasobservedusingDC/IL-10exosomes
to suppress DTH response and CIA compared with DC/IL-
10 cell treatment, making DC exosomes an even attractive
therapy than DCs.
Although not fully understood yet, the suppressive eﬀect
of DC/IL-10 exosomes is not simply due to the delivery
of the suppressive cytokine IL-10. Instead, the therapeutic
eﬀect of exosomes requires the integrity of the exosome
membrane, as repeated freeze and thaw cycles that disrupt
the exosome structure abrogated the eﬀect. The eﬀect is
also MHC class II dependent since exosomes deﬁcient in
MHC class II did not suppress DTH [36]. In addition,
the presence of B7-1/2 (CD80 and CD86) on IL-10-treated
BMDC-derived exosomes is required for their suppressiveInternational Journal of Rheumatology 3
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Figure 1: Exosome biogenesis and molecular composition. (a) Exosomes are small membrane vesicles formed by invagination of the
multivesicular bodies (MVBs) in the late endocytic compartment. They are released upon the fusion of MVBs with the plasma membrane.
(b) Exosomes are typically enriched in certain molecules including targeting/adhesion molecules, membrane traﬃcking molecules,
cytoskeletonmolecules,proteinsinvolvedinMVBformation,chaperones,cytoplasmicenzymes,signaltransductionproteins,andfunctional
mRNA and microRNA populations. ∗APC-derived exosomes contain antigen-presenting molecules including MHC class I, MHC class
II, and co-stimulatory molecules. ∗∗Exosomes also contain cell-speciﬁc antigens (e.g., tumor antigens in tumor-derived exosomes).
∗∗∗Immunosuppressive molecules such as FasL, TRAIL, or TGF-β are present on certain APC or tumor-derived exosomes.
eﬀects [39]. Thus it is possible that IL-10 treatment results
in DC-derived exosomes with a diﬀerent composition that
makes the vesicles more immunosuppressive.
2.2. DC/IL-4 Exosomes. We and others have demonstrated
that DCs genetically engineered to express the Th2 cytokine
IL-4 were an eﬀective treatment for murine CIA [22, 23].
Speciﬁcally, we found that a single i.v. injection of immature
BMDCs infected with adenoviral vector expressing IL-4
into mice with established CIA achieved almost complete
suppression of the disease lasting at least 4wk posttreatment.
The therapeutic eﬀect of the IL-4 expressing DC (DC/IL-4)
was signiﬁcantly better than repeated injection of recombi-
nant IL-4 or direct injection of adenoviral IL-4 [23]. DCs
retrovirally transduced with the IL-4 gene also reduced the
incidence and severity of CIA after a single i.p. injection
[22].Inbothstudies,DC/IL-4reducedthedisease-associated
humoral responses and conditioned splenic cells towards a
Th2-polarized response upon antigen stimulation.
Similar to the signiﬁcant immunosuppressive eﬀects of
DC/IL-4, exosomes derived from those DCs were shown
to reduce the severity and the incidence of established
CIA when delivered systemically (i.v.), and suppressed DTH
response when injected locally [40]. Suppression of the
DTH response is MHC restricted in that only syngeneic DC
exosomes, but not allogeneic exosomes, were eﬀective in
conferring immunosuppression. Furthermore, systemically
injected DC/IL-4 exosomes were found to migrate to spleen
and liver and interact with CD11c+ DCs and F4/80+
macrophages. Adoptive transfer of CD11c+ or CD3+ splenic
cells isolated from antigen-immunized mice that have been
systemically treated with exosomes into the footpad of
recipient mice signiﬁcantly reduced footpad swelling in the
DTH model, suggesting that exosomes from DC/IL-4 can
directly or indirectly modify the function of endogenous
APCs and T cells, either by inducing a regulatory subset
and/or depleting antigen-reactive Th1 cells [40].
2.3. DC/Death Ligand Exosomes. Selective inducing apopto-
sis of antigen-speciﬁc T cells by APCs genetically modiﬁed to
express death ligand (e.g., FasL and TRAIL) is an alternative
way to downregulate antigen-speciﬁc T-cell responses. DCs
genetically modiﬁed to express FasL can induce donor-
speciﬁc T-cell hyporesponsiveness to alloantigen and facil-
itate allograft survival [41]. FasL-expressing DCs are also
able to suppress collagen-reactive T cells and inhibit the
progression of murine CIA after systemic injection [26].
Exosomes derived from FasL-expressing DCs showed an
anti-inﬂammatory eﬀect in a murine DTH model upon local
administration [42]. The therapeutic eﬀect was abolished4 International Journal of Rheumatology
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Figure 2: Transmission electronic micrograph of (a) exosomes isolated from murine BMDC culture [36]. Copyright 2005. The American
Association of Immunologists, Inc. and (b) exosomes isolated from murine blood plasma [37]. Copyright 2007. The American Association of
Immunologists, Inc.
when lpr (Fas-deﬁcient) mice were used as recipients or
when exosomes were derived from the DCs of gld (FasL-
deﬁcient) mice. However, the immunosuppressive eﬀect of
FasL-deﬁcient DC exosomes could be restored by gene
transfer of FasL to DCs. The ability of DC/FasL exosomes
to suppress DTH response was also antigen speciﬁc as
optimalsuppressiveeﬀectswereachievedwhentheDCswere
prepulsed with the same antigen used for mice immuniza-
tion. Using DC and DC-derived exosomes from diﬀerent
knockout mice, the suppressive eﬀect was shown to be MHC
class II dependent, but MHC class I independent. Systemic
injection of DC/FasL exosomes was also eﬀective in treating
established murine CIA [42].
It was shown that inﬁltrating T cells present in the
synovial ﬂuid of RA patients were more susceptible to apop-
tosis induced by APO2L/TRAIL, a TNF superfamily member
capable of inducing cell apoptosis. Bioactive APO2L/TRAIL
associated with exosomes was detected in the synovial ﬂuid
of RA patients compared with synovial ﬂuid of traumatic
arthritispatients[43].Interestingly,bioactiveAPO2L/TRAIL
conjugated to the membrane of liposomes, artiﬁcial lipid
vesicles resembling exosomes, was demonstrated to sub-
stantially reduce inﬂammation after intra-articular injection
in a rabbit model of RA, more eﬀectively than soluble,
unconjugated APO2L/TRAIL. The increased bioactivity is
possibly due to the enhanced receptor cross-linking as a
result of increased local concentration of the protein upon
liposome delivery [44].
2.4. DC/IDO Exosomes. Immunoregulatory DCs expressing
the tryptophan catabolic enzyme IDO can inhibit T-cell
activation and suppress T-cell responses to auto- and
alloantigens by tryptophan starvation and/or production of
toxic metabolites [45, 46]. The immunosuppressive potency
of DCs genetically modiﬁed to express IDO and their
exosomes was also investigated in RA models. BMDCs
adenovirally transduced to express IDO and the resulting
DC/IDO exosomes both showed anti-inﬂammatory eﬀect in
murine DTH and CIA models. In addition, transduction of
DCs with the IDO inducer CTLA4-Ig resulted in induction
of IDO and the derived exosomes were also able to reduce
inﬂammation [47]. The suppressive eﬀect of DC/CTLA4-Ig
exosomes was reduced when DCs were pre-treated with the
competitive IDO inhibitor 1-MT or excessive L-tryptophan,
suggesting that the eﬀect was dependent on the IDO activity
in DCs and IDO-mediated tryptophan deprivation. Similar
to exosomes derived from DC/IL-10, the immunosuppres-
sive eﬀect of DC/IDO exosomes was partially dependent on
B7-1/2 molecules, as exosomes of DCs isolated from B7-1/2
knockout mice had an attenuated anti-inﬂammatory eﬀect
when transduced with IDO [47].
2.5. Mechanism(s) of Exosome Function. Although the exact
functional mechanism of immunosuppressive DC-derived
exosomes remains to be determined, exosomes are believed
to function more than vehicles that simply deliver immuno-
suppressive factors derived from their parental DCs. This is
evidenced by the facts that most of the suppressive eﬀects
observed have antigen speciﬁcity and are dependent on the
presenceofcertainmoleculesonexosomesaswellasinrecip-
ient animals, in particular MHC class II molecules and B7-
1/2. Furthermore, similar to direct gene transfer or DC cell
therapy [38, 48–51], distal therapeutic eﬀects (contralateral
eﬀects) were observed when exosomes were delivered locally.
However, traﬃcking analysis suggested that there is only lim-
ited cross-traﬃcking of exosomes to the contralateral lymph
node [42]. Therefore, it is likely that immunosuppressive DC
exosomes are able to modify the behavior of endogenous
immune cells, such as APCs, which then are responsible for
conferring a systemic suppressive/anti-inﬂammatory eﬀect.
TheinteractionsbetweenexosomesandAPCscouldbeatthe
membrane level or, in some cases, involve the internalizationInternational Journal of Rheumatology 5
of these vesicles where vesicle-contained proteins and RNAs
could be functionally transferred.
3. ImmunosuppressiveExosomes in
BodyFluids
In addition to exosomes derived from immunosuppressive
DCs, other sources of suppressive exosomes may also have
the potential to treat inﬂammatory arthritis diseases. Many
types of tissue- or body-ﬂuid-derived exosomes have been
found to be immunoregulatory or tolerogenic. For instance,
placenta-derived exosomes and exosomes isolated from the
maternal peripheral circulation are able to induce T-cell
signaling defects, possibly attenuating immune responses
against the fetus [52, 53]. Exosomes isolated from serum
shortly after antigen feeding are able to induce antigen-
speciﬁctoleranceinna¨ ıverecipientanimals[54].Inaddition,
exosomes isolated from the bronchoalveolar ﬂuid of mice
respiratory exposed to pollen allergen can prevent antigen-
s p e c i ﬁ ca l l e r g i cr e a c t i o n[ 55]. Also, exosomes isolated from
human breast milk and colostrum can increase the number
of T regulatory cells and inhibit eﬀector T-cell activation in
vitro [56]. Interestingly, exosomes derived from certain body
ﬂuids,inparticularconditionedbloodplasmaorserum,have
been found to reduce arthritic inﬂammation.
3.1. Plasma-Derived Exosomes. We have demonstrated that
exosome-like vesicles can be isolated from the blood plasma
of both na¨ ıve mice and antigen-immunized mice, with
certain surface protein markers including MHC class I,
MHC class II, CD11b, CD71, FasL, and CD86. Plasma-
derived exosomes isolated from mice immunized with KLH
antigen showed potent suppressive eﬀect on the KLH-
induced DTH response after local administration [37]. The
eﬀect was antigen speciﬁc since plasma-derived exosomes
isolatedfrommiceimmunized withanirrelevantantigendid
not induce eﬀective suppression. MHC class II+ exosomes
were responsible for conferring the suppressive eﬀect as
depletion of MHC class II+ exosomes from plasma-derived
exosomes abrogated this eﬀect. The anti-inﬂammatory eﬀect
also required Fas/FasL signaling. Additionally, the eﬀect
was time dependent since the optimal immunosuppres-
sive activity was obtained with exosomes isolated 14 days
after immunization. This result suggests the presence of
exosomes with antigen-speciﬁc immunosuppressive activity
in the circulation of individuals that are hyperreactive to
certain antigens. It also suggests the possibility of utilizing
autologous plasma-derived exosomes therapeutically for the
suppression of antigen-speciﬁc inﬂammation.
3.2. Clinical Studies with Serum-Derived, Anti-Inﬂammatory
Exosomes. An eﬀective method for stimulating de novo
production of anti-inﬂammatory cytokines in blood was
developed by incubating whole blood with CrSO4-treated
glass beads for a short period of time [57]. Such treatment
resulted in the robust induction of IL-1Ra and an increase
in the levels of IL-4 and IL-10 as well as certain growth
factors such as insulin-like growth factor-1 (IGF-1). This
approach for the preparation of autologous conditioned
serum (ACS) with enhanced anti-inﬂammatory cytokines
has been used for the clinical treatment of patients with
RA, osteoarthritis (OA), and spinal disorders, with eﬃcacy
and safety both observed [58, 59]. Exosomes with anti-
inﬂammatory properties were isolated from ACS and have
been tested clinically for the treatment of RA. Intra-articular
injection of these exosomes appears to be therapeutic for
RA patients who do not respond well to conventional
therapy, with reduced pain in multiple joints and decreased
inﬂammatory markers in the blood [60]. The therapeutic
use of these ACS-derived exosomes also appears to be safe,
supporting the development of similar exosome treatments
for other inﬂammatory and autoimmune diseases. The
immunosuppressive exosomes shown to be eﬀective in
treating murine and human RA are summarized in Table 1.
4. Pathogenic Exosomes
Wehavediscussedthepotentialusageofimmunosuppressive
exosomesforarthritistreatment.However,additionalstudies
have also suggested that exosomes of certain sources could
contribute to disease progression. For example, exosomes
produced by the synovial ﬁbroblasts obtained from RA
patients were found to contain a membrane form of
TNF-α, which could play a role in tissue destruction and
autoimmuneinﬂammation. TheseTNF-α positive exosomes
rendered activated T cells resistant to apoptosis, favoring
the pathogenesis of RA [61]. In addition, citrullinated
proteins, known to be autoantigens in RA, were detected
in exosomes puriﬁed from the synovial ﬂuids of RA
patients [62]. Similarly, the autoantigen nuclear protein
DEK, which contributes directly to joint inﬂammation in
juvenile arthritis (JA), is secreted in both a free form and an
exosome-associated form in the synovial ﬂuids of JA patients
[63, 64]. Exosomes containing annexins, which promote
pathological mineral formation and articular chondrocytes
destruction, were found more in the articular cartilage
in OA patients [65]. These observations demonstrate the
presence of disease-contributing exosomes, which could be
useful inﬂammation markers of arthritis diseases. In theory,
selective elimination of these exosomes would be beneﬁcial
to arthritis therapy.
5. Conclusion
Immature DCs with enhanced immunosuppressive/toler-
ogenic properties can be produced by genetic modiﬁcation
or by exposure to cytokines or cytokine inhibitors. Exosomes
derived from immunosuppressive DCs have shown thera-
peutic eﬀects comparable to or better than their parental
DCs in treating animal DTH and CIA and thus have the
potential to be used clinically for RA treatment. While DCs
manipulated ex vivo still have the risk of maturation in
inﬂammatory environment, DC-derived exosomes are more
stable following isolation and thus are safer than auto-
logous cells for in vivo administration. The unique biological
composition of exosomes also gives them a half-life that6 International Journal of Rheumatology
Table 1: Immunosuppressive exosomes for the treatment of arthritis.
Exosome
source Cell modiﬁcation/treatment Model Application and eﬀect Reference
BMDC
BMDCs transduced with
adenoviral IL-10 or treated with
rmIL-10
Mouse
Footpad injection suppressed DTH response; systemic
delivery (i.v.) ameliorated CIA progression. The eﬀect
requires exosome integrity and MHC class II and
B7-1/2 molecules.
[36, 39]
BMDC BMDCs transduced with
adenoviral IL-4 or retroviral IL-4 Mouse
Systemic injection (i.v.) reduced the incidence and
severity of established CIA; local injection suppressed
DTH response. Exosomes interacted with DCs and
macrophages in spleen and liver and were able to
modify the function of endogenous APCs and T cells.
[40]
BMDC BMDCs transduced with
adenoviral FasL Mouse
Local administration suppressed DTH response. The
eﬀect was dependent on Fas-FasL interaction and MHC
class II molecules. Systemic injection was also eﬀective
in treating established CIA.
[42]
BMDC BMDCs transduced with
adenoviral IDO or CTLA4-Ig Mouse
DC/IDO exosomes were anti-inﬂammatory in both
DTH and CIA models. DC/CTLA4-Ig exosomes
reduced DTH response. The eﬀect was dependent on
the IDO activity in DCs and partially dependent on
B7-1/2 molecules.
[47]
Blood
plasma
Exosomes were isolated from the
plasma of antigen-immunized
mice
Mouse
Local administration of plasma-derived exosomes
suppressed DTH response in an antigen-speciﬁc
manner. The eﬀect was dependent on MHC class II+
exosomes.
[37]
Serum
Exosomes were isolated from
physicochemically conditioned
autologous patient serum
Human
clinical trial
ACS exosomes exhibited anti-inﬂammatory properties.
Local injection of these exosomes was safe and
beneﬁcial to RA patients that do not respond to
conventional therapy. Reduced joint pain and decreased
blood inﬂammatory markers were observed.
[58–60]
appears longer than many cell types after injection. However,
the paucity of clinical trials using immunosuppressive DC
exosomes for arthritis treatment still prevents a comprehen-
sive evaluation of their eﬀects on human patients.
The fact that exosomes isolated directly from ACS
appears to improve disease in RA patients strongly supports
the further clinical development of immunosuppressive
exosomes. However, it is important to note that while the
clinical results are encouraging in terms of feasibility, safety,
and eﬃcacy, the blood plasma- or serum-derived exosomes
have heterogeneous cellular origins and poorly deﬁned
composition. Further investigation is needed to determine
the functional components of these therapeutic exosomes.
Takentogether,thereisconsiderableevidencesupportingthe
ability of immunosuppressive exosomes to help control the
overreactive immune system. Compared with gene and cell
therapies, exosome-based therapy could provide a new and
safe therapeutic approach for arthritis.
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